Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-α Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction

Abstract

Objective. To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-α levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). Methods. The clinical data of 84 ACI patients treated in our hospital from August 2020 to August 2021 were retrospectively analyzed, and they were divided into the routine group (n = 42) and the combined group (n = 42) according to the order of admission. Both groups were treated with routine clinical treatment, and the combined group was additionally treated with edaravone combined with anticoagulant therapy. Serum samples were collected from both groups after treatment. ELISA was used to detect the serum inflammatory factor levels, and the modified Barthel index score was used to evaluate the ADL of patients. Results. Compared with the routine group, the combined group achieved obviously lower levels of PMA, CD62p, and serum inflammatory factors after treatment ( P < 0.001 ), higher modified Barthel score after treatment ( P < 0.001 ), lower plasma viscosity, platelet aggregation rate, and plasma fibrinogen level after treatment ( P < 0.001 ), and higher clinical overall efficacy ( P < 0.05 ). Conclusion. Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients. This strategy greatly reduces the platelet-activating factor levels of patients and improves the comprehensive clinical efficacy, and its further research will help to establish a better solution for these patients.

Intravenous Thrombolysis Combined with Arterial Thrombolysis (Bridging Therapy) Effectively Improves Vascular Recanalization Rate in Patients with Cerebral Infarction

“…Inflammation, which is positively correlated with the severity of cerebral infarction, is essential in the pathogenesis and progression of the disease and acts as an independent pathogenic factor for clinical prognosis and disease outcome assessment of patients [ 22 ]. CRP, IL-6, and TNF- α , the most representative markers of inflammatory responses, have a direct relationship with cerebral infarction and have gradually become the indicators that researchers and clinical medical staff focus on and attach importance to [ 23 ]. Our findings revealed statistically reduced inflammatory factors IL-6, TNF- α , and hs-CRP in both groups after treatment, with more obvious decreases in the observation group ( P < 0.05), which suggested that bridging therapy can relieve inflammatory responses in ACI patients and reduce the high expression of inflammatory factors.…”